HotSpot Therapeutics is a biotechnology company pioneering the discovery and development of first-in-class allosteric therapies targeting nature’s regulatory sites.
HotSpot Therapeutics is creating a new paradigm for allosteric medicines that exploits natural control mechanisms.
HotSpot Therapeutics was founded in 2017 by Jonathan Montagu and Geraldine Harriman. The company is headquartered in Boston, Massachusetts.
HotSpot's Smart Allostery™ technology platform utilizes AI-driven data mining of large and highly diverse data sets to identify pockets that matter on proteins, integrated with a tailored pharmacology toolkit and bespoke chemistry to rapidly deliver superior hotspot-targeted small molecules.
The Smart Allostery™ platform encompasses a broad suite of AI-enabled technologies and the industry's largest and most diverse chemical library tailored to hotspots. HotSpot has successfully exploited natural hotspots across multiple classes, including E3 ligases, kinases, and transcription factors.
HotSpot has established a product pipeline of first-in-class small molecules for the treatment of cancer and autoimmune diseases, each enabled by precision and patient-targeted clinical design.
HotSpot is backed by Pivotal bioVenture Partners, Sofinnova Partners, LSP, B Capital Group, Atlas Venture, Monashee Investment Management, S.R. One, Tekla Capital Management, and others. The company $100M in Series C round on Nov 29, 2021. This brings HotSpot's total funding to $210M to date.